Urogen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research report released on Friday morning,Benzinga reports. The firm currently has a $33.00 price objective on the stock.

Several other brokerages also recently weighed in on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday. Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Urogen Pharma Price Performance

NASDAQ:URGN opened at $20.00 on Friday. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The stock has a market capitalization of $936.20 million, a PE ratio of -5.78 and a beta of 1.29. The stock’s 50-day moving average price is $23.13 and its 200-day moving average price is $20.31.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to analyst estimates of $34.09 million. Sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the insider directly owned 139,025 shares in the company, valued at $3,475,625. The trade was a 6.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.70% of the stock is owned by company insiders.

Institutional Trading of Urogen Pharma

Hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. raised its position in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. State of Wyoming acquired a new stake in Urogen Pharma during the third quarter worth $66,000. Russell Investments Group Ltd. raised its position in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the period. Strs Ohio purchased a new stake in Urogen Pharma in the third quarter valued at $76,000. Finally, CWM LLC lifted its stake in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after purchasing an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.